Literature DB >> 11719429

WWOX, the FRA16D gene, behaves as a suppressor of tumor growth.

A K Bednarek1, C L Keck-Waggoner, R L Daniel, K J Laflin, P L Bergsagel, K Kiguchi, A J Brenner, C M Aldaz.   

Abstract

We recently reported the cloning of WWOX, a gene that maps to the common fragile site FRA16D region in chromosome 16q23.3-24.1. It was observed that the genomic area spanned by WWOX is affected by chromosomal translocations and homozygous deletions. Furthermore, the high incidence of allelic loss in breast, ovarian, prostate, and other cancers affecting this region suggests that WWOX is a candidate tumor suppressor gene. Expression of WWOX is highly variable in breast cancer cell lines, with some cases showing low or undetectable levels of expression. In this report, we demonstrate that ectopic WWOX expression strongly inhibits anchorage-independent growth in soft agar of breast cancer cell lines MDA-MB-435 and T47D. Additionally, we observed that WWOX induces a dramatic inhibition of tumorigenicity of MDA-MB-435 breast cancer cells when tested in vivo. We also detected the common occurrence of aberrant WWOX transcripts with deletions of exons 5-8 or 6-8 in various carcinoma cell lines, multiple myeloma cell lines, and primary breast tumors. These aberrant mRNA forms were not detected in normal tissues. Interestingly, we further observed that proteins encoded by such aberrant transcripts display an abnormal nuclear localization in contrast to the wild-type WWOX protein that localizes to the Golgi system. Our data indicate that WWOX behaves as a potent suppressor of tumor growth and suggest that abnormalities affecting this gene at the genomic and transcriptional level may be of relevance in carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11719429

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  101 in total

1.  Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression.

Authors:  Kyle C Kurek; Sara Del Mare; Zaidoun Salah; Suhaib Abdeen; Hussain Sadiq; Suk-Hee Lee; Eugenio Gaudio; Nicola Zanesi; Kevin B Jones; Barry DeYoung; Gail Amir; Mark Gebhardt; Matthew Warman; Gary S Stein; Janet L Stein; Jane B Lian; Rami I Aqeilan
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

2.  Deletion and mutation of WWOX exons 6-8 in human non-small cell lung cancer.

Authors:  Yulong Zhou; Yongjian Xu; Zhenxiang Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

3.  Characterization of the tumor suppressor gene WWOX in primary human oral squamous cell carcinomas.

Authors:  Flávio J Pimenta; Dawidson A Gomes; Paolla F Perdigão; Alvimar A Barbosa; Marco A Romano-Silva; Marcus V Gomez; C Marcelo Aldaz; Luiz De Marco; Ricardo S Gomez
Journal:  Int J Cancer       Date:  2006-03-01       Impact factor: 7.396

4.  WWOX protein expression in normal human tissues.

Authors:  Maria I Nunez; John Ludes-Meyers; C Marcelo Aldaz
Journal:  J Mol Histol       Date:  2006-08-29       Impact factor: 2.611

5.  An AT-rich sequence in human common fragile site FRA16D causes fork stalling and chromosome breakage in S. cerevisiae.

Authors:  Haihua Zhang; Catherine H Freudenreich
Journal:  Mol Cell       Date:  2007-08-03       Impact factor: 17.970

6.  ASCIZ regulates lesion-specific Rad51 focus formation and apoptosis after methylating DNA damage.

Authors:  Carolyn J McNees; Lindus A Conlan; Nora Tenis; Jörg Heierhorst
Journal:  EMBO J       Date:  2005-06-02       Impact factor: 11.598

Review 7.  Structural insights into the functional versatility of WW domain-containing oxidoreductase tumor suppressor.

Authors:  Amjad Farooq
Journal:  Exp Biol Med (Maywood)       Date:  2015-02-07

Review 8.  Strategies of oncogenic microbes to deal with WW domain-containing oxidoreductase.

Authors:  Yao Chang; Yu-Yan Lan; Jenn-Ren Hsiao; Nan-Shan Chang
Journal:  Exp Biol Med (Maywood)       Date:  2014-12-07

9.  Low levels of WWOX protein immunoexpression correlate with tumour grade and a less favourable outcome in patients with urinary bladder tumours.

Authors:  D Ramos; M Abba; J A López-Guerrero; J Rubio; E Solsona; S Almenar; A Llombart-Bosch; C M Aldaz
Journal:  Histopathology       Date:  2008-04-29       Impact factor: 5.087

Review 10.  WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies.

Authors:  C Marcelo Aldaz; Brent W Ferguson; Martin C Abba
Journal:  Biochim Biophys Acta       Date:  2014-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.